Adlai Nortye Ltd ADR (ANL)
Adlai Nortye Ltd ADR (NASDAQ: ANL) is a depositary receipt tied to Adlai Nortye Ltd., a clinical-stage biotechnology company focused on researching and developing pharmaceutical products. The company’s lead candidate, AN2025, is a pan-phosphoinositide 3-kinase inhibitor being evaluated in Phase III trials for recurrent or metastatic head and neck squamous cell carcinoma. Adlai Nortye is also advancing AN0025, a small-molecule prostaglandin E receptor 4 antagonist in Phase Ib studies across several cancer indications, and AN4005, an oral small-molecule PD-L1 inhibitor in Phase I trials. Its preclinical pipeline includes AN8025, a multifunctional antibody candidate, and AN9025, an oral pan-KRAS inhibitor. Founded in 2004, the company is based in Grand Cayman, the Cayman Islands.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ANL
|
$10.75
|
-31.7% Downside
|
Overvalued
|
$29.50
|
87.4% Upside
|
Bargain
|
Fair
|
0.0%
|
December 2, 2026
|
4.7x
|
55.9x
|
1.014 B
|
802.4 M
|
2.6%
|
73.4%
|
8.9
|
150.3%
|
